ALRISE Biosystems GmbH, Competence in Drug Delivery

ALRISE, with its innovative ImSus® technology, sets itself apart from its competitors in that:

Its formulation will not adversely affect the safety profile of the medications, since excipients used in the process are safe (GRAS) and have been used in products that have been approved by the FDA
Activity of process sensitive medications such as peptides or proteins is preserved by ALRISE's rapid and mild encapsulation process

ALRISE's encapsulation process can be used both for biologicals (peptides / proteins) and especially for poorly soluble drugs (small molecules)
Initial burst free formulations can be produced
Its encapsulation efficiency of 75 to 100% is unrivalled by any other known technology
Morphology, particle permeability and the size of the final formulation can be reproducibly controlled
Homogeneity of particle morphology and size is the highest in its class
It is the only available technology that can produce micro- as well as nano-particles
It is applicable not only to parenteral and oral but potentially to any drug delivery route

In contrast to its competitors, ALRISE uses a one-pot process which is easy to handle and can easily be up-scaled with minimum effort and cost
A process time of minutes is an order of magnitude faster than that of the competing technologies
ImSus® technology uses smaller volumes of surfactant and reduces chemical waste generated during the process, it decreases waste-associated costs and minimizes negative impacts to environment

Technological Advantages